This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
, No Gclids
Disease Info Card
Leishmaniasis, Visceral
Information about Leishmaniasis, Visceral: characteristics, related genes and pathways, plus antibodies you can use for research. This page is being enriched constantly, if you see some information you would like this page to include please send your suggestions to us.
Overview of Leishmaniasis, Visceral
Most recent studies have shown that Leishmaniasis, Visceral shares some biological mechanisms with acquired-immunodeficiency-syndrome, aids-related-opportunistic-infections, anemia, coinfection, communicable-diseases, dog-diseases, endemic-diseases, hiv-infections, immunologic-deficiency-syndromes, infective-disorder, leishmania-infantum-disease, leishmaniasis, leishmaniasis-cutaneous, malaria, mucocutaneous-leishmaniasis, pancytopenia, post-kala-azar-dermal-leishmaniasis, tuberculosis, zoonoses.
Among the many pathways, these few ones have gauged particular interests from scientists studying Leishmaniasis, Visceral, and have been seen in publications frequently: Cell Activation, Cell Death, Cell Proliferation, Coagulation, Cytokine Production, Drug Resistance, Granuloma Formation, Humoral Immune Response, Hypersensitivity, Immune Response, Inflammatory Response, Localization, Lymphocyte Proliferation, Macrophage Activation, Parasitism, Pathogenesis, Phagocytosis, Secretion, Transport, Virulence
Quite a number of genes have been found to play important roles in Leishmaniasis, Visceral, such as ALB, CD4, CD8A, DMBT1, FMN1, FOXC2, IFNG, IL10, IL2, IL4, IL6, MLC1, NOS2, PKD2L1, RNF7, SAG, SLC11A1, SLC6A3, TNF. See what Boster has to offer for the research of these genes by clicking the gene name links below and view a more detailed info card/product listing for that gene.
In a later update, we will include information such as current drugs and therapy solutions as well as on-going and past clinical trials for this disease. Plesae stay updated.